Asger B. L.
- Country
- Denmark
- Department
- Center for Clinical Metabolic Research, Gentofte Hospital
Research Overview
- Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial
- Evaluation of Atorvastatin in Modulating Bile Acid Synthesis in Patients with Moderate to Severe Bile Acid Diarrhoea: A Dose-Response Study
Data & Insights
Has run more than one trial at 1 of 3 partner sites.
Specializations
Metabolic Health Research
This investigator specializes in metabolic disorders with a particular focus on weight management and obesity treatment. Their research encompasses comprehensive approaches to weight reduction through various therapeutic interventions.
- Obesity Management
- Weight Loss Interventions
- Metabolic Health Assessment
Their work involves evaluating novel therapeutic combinations for weight management in individuals with obesity.
Diabetes Research
The investigator conducts studies in type 1 diabetes with particular attention to inflammatory mechanisms and their role in disease progression. Their research explores innovative therapeutic approaches for managing diabetes-related complications.
- Inflammatory Biomarkers
- Diabetes Treatment Innovation
- Therapeutic Drug Repurposing
Their research extends to investigating anti-inflammatory interventions in diabetes management.
Therapeutic Innovation
The investigator evaluates combination therapies and novel treatment approaches for metabolic conditions. Their work includes assessment of both established and experimental therapeutic agents.
- Combined Treatment Approaches
- Therapeutic Efficacy Assessment
- Long-term Treatment Outcomes
Their research encompasses the evaluation of both systemic and targeted therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.